(Hypertension. 1997;29:45.)
© 1997 American Heart Association, Inc.
Research Articles (Issue 1, Part 1) |
Vascular Aldosterone in Genetically Hypertensive Rats
the Second Department of Internal Medicine (Y.T., I.M., S.I., K.F., H.H., T.Y., H.M.) and Department of Health Sciences (Y.T.), School of Medicine, Kanazawa University, and KKR Hokuriku Hospital (R.T.), Kanazawa, Japan.
Correspondence to Yoshiyu Takeda MD, Second Department of Internal Medicine, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920, Japan.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
We have reported that aldosterone is synthesized and cytochrome P450aldo mRNA exists in the vasculature. To clarify the pathophysiological role of vascular aldosterone in hypertension, we compared aldosterone production in the mesenteric arteries of stroke-prone spontaneously hypertensive rats (SHRSP) with that in Wistar-Kyoto rats (WKY). The expressions of mRNA of cytochrome P450aldo, mineralocorticoid receptor, and
1 Na,K-ATPase in the mesenteric arteries were compared between the two groups. Aldosterone concentration in the perfusate of the vasculature was measured by radioimmunoassay after purification with high-performance liquid chromatography. Cytochrome P450aldo and mineralocorticoid receptor mRNA levels were quantified by Southern blot analysis of the products of reverse-transcribed polymerase chain reaction. Levels of 1 Na,K-ATPase mRNA were measured by Northern blot analysis. Vascular aldosterone and cytochrome P450aldo mRNA levels of 2-week-old SHRSP were significantly increased compared with those of age-matched WKY. However, vascular aldosterone in 4- and 9-week-old SHRSP did not differ from that in age-matched WKY. Expression levels of mineralocorticoid receptor mRNA in the vasculature of 4- and 9-week-old SHRSP were significantly increased compared with those in age-matched WKY. Concentrations of vascular 1 Na,K-ATPase mRNA of 2-, 4-, and 9-week-old SHRSP also were significantly higher than those in age-matched WKY. These results suggest that vascular aldosterone contributes to the pathophysiology of hypertension in SHRSP in the early stage.
Key Words: aldosterone • rats, inbred SHR • receptors, mineralocorticoid • Na+,K+-exchanging ATPase • RNA, messenger
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The renin-angiotensin-aldosterone system plays an important role in the control of BP and water and electrolyte balance. It has been shown that all components of the renin-angiotensin system are expressed in both the vascular wall and heart and function on an autocrine-paracrine level.1 2 3 4 The physiological functions of such a locally acting tissue renin-angiotensin system have been postulated but are still subject to further investigation. We have reported that aldosterone, synthesized in the vasculature, is partly controlled by Ang II and participates in the development of vascular hypertrophy in relative accordance with Ang II.5 6 The spontaneously hypertensive rat (SHR) has been studied extensively and suggested as a model for the investigation of hypertension in humans. The SHRSP, a substrain of SHR developed by Okamoto et al,7 is a useful model of human malignant hypertension. To clarify the pathophysiological role or roles of vascular aldosterone in hypertension, we compared aldosterone production in mesenteric arteries of 2-, 4-, and 9-week-old SHRSP with that in age-matched WKY. We compared the expression of mRNA of cytochrome P450aldo (CYP11B2), MCR, and
1 Na,K-ATPase in the mesenteric arteries between the two groups at each age. |
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Two-, 4-, and 9-week-old SHRSP (n=26 in each group) and age-matched WKY/Izm8 (n=26 in each group) donated by Disease Model Cooperative Research Association (Kyoto, Japan) were housed in metabolic cages with free access to tap water and normal rat chow (0.1 mmol/g sodium, 0.24 mmol/g potassium; Nippon Charles River). SHRSP were kindly donated by Dr Kozo Okamoto (Kinki University School of Medicine, Osaka, Japan). Rats were maintained in a constant-temperature environment, with a 12-hour light/dark cycle.
BP was determined by a plethysmographic tail-cuff method previously reported.9 Blood was collected from the tail vein as previously reported.9 Plasma concentrations of corticosterone and aldosterone were estimated by radioimmunoassay after extraction with a Sep-Pak C18 cartridge (Waters).10
Eight rats from each group were used for the experiments involving mesenteric arterial perfusion. After the rat was put under pentobarbital anesthesia, the superior mesenteric artery was isolated at its junction with the abdominal aorta and freed of fat and connective tissue by the method of McGregor11 with minor modifications as we have previously reported.12 Briefly, the isolated artery with the second branch was perfused with Krebs-Ringer solution, pH 7.4, at a temperature of 37°C and oxygenated with a 95% O2/5% CO2 gas mixture at a constant flow rate of 3 mL/min. The perfusion pressure was constantly monitored and recorded by means of a pressure transducer connected to a polygraph (RM 600, Nihon-Koden). After 30 minutes of equilibration, the perfusate was collected for 4 hours. The perfusate with tritium-labeled aldosterone (3000 cpm, Amersham Japan) used for recovery monitoring was extracted with a Sep-Pak C18 cartridge in preparation for chromatography with a reversed-phase high-performance liquid chromatographic (HPLC) system. Methanol/water (40%/100%) was used as the mobile phase at a flow rate of 1.5 mL/min for 60 minutes.5 The retention times of 18-hydroxycorticosterone, aldosterone, corticosterone, deoxycorticosterone, progesterone, and pregnenolone were 35, 32, 43, 49, 55, and 59 minutes, respectively. The aldosterone concentration in the perfusate from SHRSP and WKY of each age was measured by radioimmunoassay after HPLC separation. After these experiments on the perfusate, the mesenteric artery was homogenized in 10 mL Krebs-Ringer buffer solution in a tissue grinder. Protein assay was performed according to the method of Bradford.13
Six rats from each group were used for quantification of mRNA of CYP11B2 and MCR, and 12 rats were used for measurement of 1 Na,K-ATPase mRNA in the mesenteric arteries. Mesenteric arteries with the first branch were removed immediately after the rat was decapitated and were freed of fat and connective tissue. The tissue was promptly weighed, frozen in liquid nitrogen, and stored at -80°C before use. Total RNA from rat mesenteric arteries was separated with guanidine thiocyanate followed by centrifugation in a CsCl solution.13 One microgram of total RNA was incubated at 42°C for 60 minutes with 2.5 U Moloney murine leukemia virus (MMLV) reverse transcriptase (RT) (Perkin-Elmer Japan) in a 20-µL reaction mixture containing a random hexanucleotide primer. After incubation for 5 minutes at 99°C, the single-stranded cDNA in the 20-µL reaction mixture was amplified with the polymerase chain reaction (PCR) mixture containing 0.2 mmol/L of each dNTP. The reaction was followed by incubation at 92°C for 3 minutes and 30 cycles of the following sequential steps: 92°C for 1 minute, 60°C for 1 minute, and 72°C for 2 minutes.
The sequences of sense and antisense primers for CYP11B2 were 5'-ACTCCGTGGCCTGAGACG-3' and 5'-TTCAAGTC-CACCACACAG-3', respectively, according to the sequences published by us.14 The MCR sense primer was 5'-GTGTGTGA-GATGAGGCTTCTGGG-3' and the antisense primer was 5'-TTCTTCCTGGCCGGTATCTCCCG-3' according to the sequences published by Loffreda et al.15 We performed RT-PCR using ß-actin as an internal standard. The primers were defined as previously reported by Krapf and Solioz.16 The RT-PCR products in 20-µL aliquots were electrophoresed on a 1.5% agarose gel and transferred to nylon membranes. The membranes were prehybridized in 50% formamide, 5x saline/sodium/phosphate/EDTA, 5x Denhardt's reagent, 1% sodium dodecyl sulfate (SDS), and 0.5 g/L salmon sperm DNA at 50°C for 6 hours. They were then hybridized in the same buffer at 50°C for 15 hours with a specific oligoprobe for CYP11B2, MCR, or ß-actin that had been end-labeled with [32P]ATP (6000 Ci/mmol, New England Nuclear) using a 5'-end oligonucleotide labeling kit. Next, the membrane was washed twice in 2x SSC/0.1% SDS at room temperature for 20 minutes and twice in 0.1x SSC/0.1% SDS at 50°C for 20 minutes in preparation for autoradiography. The hybridized signals were analyzed with a BAS 2000 Bioimaging Analyzer (Fuji Photo Film Co Ltd). The oligonucleotide probes specific for CYP11B2 and MCR were 5'-TGGATGTCCAGCAAAGTC-3' and 5'-TGGCAGCGAAACAGATGATC-3', respectively.14
Pooled poly(A)+ RNAs (5 µg per lane, n=4) of mesenteric arteries of three rats from each experimental group were separated by formaldehyde/agarose gel electrophoresis, transferred to a nylon membrane (Hybond-N+, Amersham Japan), and hybridized with 32P-labeled cDNA probes. The filters were washed and radioactive bands detected by autoradiography. The 1 Na,K-ATPase cDNA probe used in these experiments was obtained from an EcoRI fragment of rat 1 Na,K-ATPase cDNA. The hybridized signals were analyzed with a BAS 2000 Bioimaging Analyzer. For quantification of relative levels of expression of 1 Na,K-ATPase mRNA, the autoradiographic signals were standardized to signals determined from ß-actin mRNA in each preparation to control for amounts of RNA loaded per lane.
The protocol was approved by the Animal Research Committee of the School of Medicine, Kanazawa University.
The time course of aldosterone production in isolated perfused mesenteric preparations was examined up to 5 hours. Aldosterone production was found to be stable up to 4 hours (data not shown). Data are expressed as mean±SE. The significance of differences was assessed by one-way ANOVA and Wilcoxon's unpaired t test. A value of P<.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The sensitivity of the aldosterone assay was 30 fmol. The overall recovery was 70%; the interassay variation was 13.5%; and the intra-assay variation was 9.5% for aldosterone in the HPLC system.
The Table summarizes body weight, systolic BP, heart rate, and plasma concentrations of aldosterone and corticosterone in the experimental groups. BP in 9-week-old SHRSP was significantly higher than that of WKY (P<.05). Plasma concentrations of corticosterone did not differ significantly between SHRSP and WKY of each age. The plasma aldosterone concentration was significantly higher in 9-week-old SHRSP than in WKY of the same age (P<.05).
|
The production level of aldosterone from the mesenteric arteries of 4- and 9-week-old SHRSP did not differ significantly from that in WKY of the same age (Fig 1). However, 2-week-old SHRSP showed a significantly higher production of aldosterone from their vasculature than WKY of the same age (P<.05) (Fig 1). The concentration of CYP11B2 mRNA in the mesenteric arteries of 2-week-old SHRSP was significantly increased compared with WKY of the same age (P<.05) (Fig 2). Although MCR mRNA levels in the mesenteric arteries of 2-week-old SHRSP did not differ from those of age-matched WKY, the relative concentrations of MCR mRNA in 4- and 9-week-old SHRSP were significantly higher than those in WKY at each age (P<.05) (Fig 3). Fig 4 shows the results of Northern blot analysis and 1 Na,K-ATPase mRNA concentrations in the mesenteric arteries of SHRSP and WKY. Concentrations of 1 Na,K-ATPase mRNA in the mesenteric arteries of 2-, 4-, and 9-week-old SHRSP were significantly increased compared with those in age-matched WKY (P<.05).
|
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
There has been increasing evidence that mineralocorticoids, acting directly on peripheral vascular tissue, cause hypertension.17 18 Tobian and Redleaf19 have proposed that aldosterone affects salt and water balance in vascular cells and thereby influences vessel lumen size. Hansen and Bohr20 have proposed a direct mineralocorticoid effect on vascular tone and contractility. We have reported that aldosterone increased tritiated leucine incorporation in vascular smooth muscle cells, which was inhibited by a specific aldosterone antagonist.6 Studying rat mesenteric arteries, Funder et al21 found that vascular type I aldosterone binding sites were physiological MCRs. We detected the expression of MCR mRNA in cultured vascular smooth muscle cells. These findings suggest a local rather than a systemic effect of aldosterone via MCRs.
The SHRSP serves as a model of human malignant hypertension. However, the pathophysiological factors that cause malignant hypertension in the SHRSP remain to be established. Adrenal mineralocorticoids are thought to be responsible for the abnormal vascular reactivity observed in the SHRSP.22 Howe et al23 have reported that plasma catecholamine concentrations are higher in SHRSP than WKY. Adrenomedullary activity is enhanced in the SHRSP, along with the adrenal renin-angiotensin system.24
In the present study, vascular aldosterone levels were increased in young prehypertensive SHRSP. Increased levels of CYP11B2 mRNA in the vasculature of SHRSP suggest that local synthesis of aldosterone is increased. The expression of 1 Na,K-ATPase mRNA was increased in the vasculature of SHRSP of the same age. Aldosterone directly stimulates Na,K-ATPase gene expression and induces activation and accumulation in vascular smooth muscle cells.25 26 Locally increased levels of aldosterone in the vasculature may contribute to the pathophysiology in SHRSP in the early stage. In 9-week-old SHRSP, vascular aldosterone production did not differ from that in WKY of the same age. However, the expressions of both 1 Na,K-ATPase mRNA and MCR mRNA in the vasculature were increased. Plasma aldosterone concentrations also were elevated in 9-week-old SHRSP compared with those in age-matched WKY. Kim et al24 reported that plasma aldosterone concentration is high in 18-week-old SHRSP with malignant hypertension. These findings suggest that circulating rather than vascular aldosterone contributes to the sustained hypertension in SHRSP.
In 4-week-old SHRSP, circulating and vascular aldosterone levels did not differ from those in WKY of the same age. However, 1 Na,K-ATPase and MCR mRNA expressions were increased compared with expressions in WKY. These findings suggest the increased aldosterone effect in the vasculature of SHRSP. 11ß-Hydroxysteroid dehydrogenase has been proposed to play an important role in aldosterone target cells by degrading endogenous glucocorticoids, thus allowing aldosterone to bind to the relatively nonselective MCR.27 28 Previously, we have reported that vascular 11ß-hydroxysteroid dehydrogenase activity is lower in SHR.29 Locally increased glucocorticoids also may affect vascular tone and contractility via MCRs.
Recently, the hypothesis that a local renin-angiotensin system plays an important role in BP regulation has received strong support from studies in rats transgenic for the mouse Ren-2 gene.30 These rats develop severe hypertension despite low or normal plasma renin, kidney tissue renin, and plasma Ang II concentrations.31 Furthermore, the BP is lowered by treatment with angiotensin-converting enzyme inhibitors.31 It is not known whether endogenous vascular aldosterone is sufficient to cause vascular remodeling or contractility. We have reported that aldosterone participates in the development of vascular hypertrophy in relative accordance with Ang II.6 Vascular Ang II and aldosterone may contribute to hypertension in this model. Further study is necessary to clarify the role of vascular aldosterone in hypertension using transgenic models that overexpress aldosterone in their vasculature.
|
Selected Abbreviations and Acronyms |
|---|
|
Received April 29, 1996;
first decision May 16, 1996; first decision August 14, 1996;
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues. J Clin Invest. 1993;91:2058-2064.[Medline] [Order article via Infotrieve]
2. Dzau VJ. Circulating versus local renin-angiotensin-system in cardiovascular homeostasis. Circulation. 1988;77(suppl I19):I4-I13.
3. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1977;79:1-6.
4. Lokett MF, Rerallack RW. Factors controlling the secretion of a substance biologically resembling the 18-monoacetate of d-aldosterone by heart muscle. J Physiol. 1970;210:717-725.
5. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh F-Y, Takeda R. Production of aldosterone in isolated rat blood vessels. Hypertension. 1995;25:170-173.
6. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Yamamoto H, Takeda R. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269:24316-24320.
7. Okamoto Y, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rats (SHR). Circ Res. 1974;34(suppl I):I-143-I-153.
8. Tamada T, Nara Y, Mashimo T, Matsumoto C, Ikeda K, Sawamura M, Yamori Y. Comparison of the genetic background among WKY and SHR (SP) using microsatellite markers. Jpn Heart J. 1996;37:552.
9. Miyamori I, Brown MJ, Dollery CT. Single-dose captopril administration in DOCA/salt rats: reduction of hypotensive effect by indomethacin. Clin Exp Hypertens. 1980;2:935-945.[Medline] [Order article via Infotrieve]
10. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Takeda R. Gene expression of 11ß-hydroxysteroid dehydrogenase in the mesenteric arteries of genetically hypertensive rats. Hypertension. 1994;23:577-580.
11. McGregor DD. The effect of sympathetic nerve stimulation on vasoconstrictor responses in perfused mesenteric blood vessels of the rat. J Physiol. 1965;117:21-30.
12. Takeda Y, Miyamori I, Yoneda T, Takeda R. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats. Life Sci. 1991;48:2553-2556.[Medline] [Order article via Infotrieve]
13. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle protein-dye binding. Anal Biochem. 1976;72:248-252.[Medline] [Order article via Infotrieve]
14. Takeda Y, Miyamori I, Yoneda T, Iki K, Blair IA, Hsieh F-Y, Takeda R. Synthesis of corticosterone in the vascular wall. Endocrinology. 1994;135:2283-2286.[Abstract]
15. Loffreda N, Eldon P, Auzou G, Frelin C, Claire M. Corticosteroid receptors in cells derived from rat brain microvessels: mRNA identification and aldosterone binding. Am J Physiol. 1992;262:C156-C163.[Medline] [Order article via Infotrieve]
16. Krapf R, Solioz M. Na/H antiporter mRNA expression in single nephron segments of rat kidney cortex. J Clin Invest. 1991;88:783-788.[Medline] [Order article via Infotrieve]
17. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.[Medline] [Order article via Infotrieve]
18. Kornel L, Rafelson ME, Hayashi T, Kanamarlapudi N, Anderson KM. Arterial receptors for adrenal steroids and transport of electrolytes in vascular smooth muscle. Clin Physiol Biochem. 1988;6:188-200.[Medline] [Order article via Infotrieve]
19. Tobian L, Redleaf PD. Effect of hypertension on arterial wall electrolytes during deoxycorticosterone administration. Am J Physiol. 1957;189:451-454.
20. Hansen TR, Bohr DF. Hypertension, transmural pressure, and vascular smooth muscle response in rats. Circ Res. 1975;36:590-598.
21. Funder JW, Pearce PT, Smith R, Campbell J. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology. 1989;125:2224-2226.
22. Brunner CA, Webb RC. Adrenal-dependent change in vascular reactivity in stroke-prone spontaneously hypertensive rats. Hypertension. 1988;12:388-392.
23. Howe PRC, Rogers PF, Morris MJ, Chalmers JP, Smith RM. Plasma catecholamines and neuropeptide-Y as indices of sympathetic nerve activity in normotensive and stroke-prone spontaneously hypertensive rats (SHR). J Cardiovasc Pharmacol. 1986;8:1113-1121.[Medline] [Order article via Infotrieve]
24. Kim S, Tokuyama M, Hosoi M, Yamamoto K. Adrenal and circulating renin-angiotensin system in stroke-prone hypertensive rats. Hypertension. 1992;20:280-291.
25. Oguchi A, Ikeda U, Kanbe T, Tsuruya Y, Yamamoto K, Kawakami K, Medford RM, Shimada K. Regulation of Na-K-ATPase gene expression by aldosterone in vascular smooth muscle cells. Am J Physiol. 1993;265:H1167-H1172.[Medline] [Order article via Infotrieve]
26. Beron J, Verrey F. Aldosterone induces early activation and late accumulation of Na-K-ATPase at surface of A6 cells. Am J Physiol. 1994;266:C1278-C1290.[Medline] [Order article via Infotrieve]
27. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-585.
28. Rusvai E, Náray-Fejes-Tóth A. A new isoform of 11ß-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem. 1993;268:10717-10720.
29. Takeda Y, Yoneda T, Miyamori I, Gathiram P, Takeda R. 11ß-Hydroxysteroid dehydrogenase activity in mesenteric arteries of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993;20:627-631.[Medline] [Order article via Infotrieve]
30. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990;344:541-544.[Medline] [Order article via Infotrieve]
31. Carretero OA, Scicli AG. Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension. Hypertension. 1991;18(suppl I):I-58-I-69.
This article has been cited by other articles:
 |
|
 |
|
  A. Karagiannis, K. Tziomalos, A. I Kakafika, V. G Athyros, F. Harsoulis, and D. P Mikhailidis Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas Endocr. Relat. Cancer, September 1, 2008; 15(3): 693 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Siragy and C. Xue Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats Exp Physiol, July 1, 2008; 93(7): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Marcy and T. L. Ripley Aldosterone antagonists in the treatment of heart failure Am. J. Health Syst. Pharm., January 1, 2006; 63(1): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, and G. S. Francis Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure Mayo Clin. Proc., December 1, 2005; 80(12): 1623 - 1630. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M C Connell and E. Davies The new biology of aldosterone J. Endocrinol., July 1, 2005; 186(1): 1 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fiebeler, J. Nussberger, E. Shagdarsuren, S. Rong, G. Hilfenhaus, N. Al-Saadi, R. Dechend, M. Wellner, S. Meiners, C. Maser-Gluth, et al. Aldosterone Synthase Inhibitor Ameliorates Angiotensin II-Induced Organ Damage Circulation, June 14, 2005; 111(23): 3087 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Funder Cardiac Synthesis of Aldosterone: Going, Going, Gone... ? Endocrinology, November 1, 2004; 145(11): 4793 - 4795. [Full Text] [PDF]
|
|
|
|
|
|
E. P. Gomez-Sanchez, N. Ahmad, D. G. Romero, and C. E. Gomez-Sanchez Origin of Aldosterone in the Rat Heart Endocrinology, November 1, 2004; 145(11): 4796 - 4802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Vasan, J. C. Evans, M. G. Larson, P. W.F. Wilson, J. B. Meigs, N. Rifai, E. J. Benjamin, and D. Levy Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive Persons N. Engl. J. Med., July 1, 2004; 351(1): 33 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K Shieh, E. Kotlyar, and F. Sam Aldosterone and cardiovascular remodelling: focus on myocardial failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 3 - 13. [Abstract] [PDF]
|
|
|
|
|
|
B. Pitt, C. T Stier Jr, and S. Rajagopalan Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 164 - 168. [Abstract] [PDF]
|
|
|
|
|
|
N. J. Brown Eplerenone: Cardiovascular Protection Circulation, May 20, 2003; 107(19): 2512 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rocha, A. E. Rudolph, G. E. Frierdich, D. A. Nachowiak, B. K. Kekec, E. A. G. Blomme, E. G. McMahon, and J. A. Delyani Aldosterone induces a vascular inflammatory phenotype in the rat heart Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1802 - H1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Epstein, J. Almirall, T. Lopez, A. Chrysostomou, and G. Becker Spironolactone and ACE Inhibition in Chronic Renal Failure N. Engl. J. Med., February 7, 2002; 346(6): 456 - 457. [Full Text] [PDF]
|
|
|
|
|
|
G.-M. Wang, R.-S. Ge, S. A. Latif, D. J. Morris, and M. P. Hardy Expression of 11{beta}-Hydroxylase in Rat Leydig Cells Endocrinology, February 1, 2002; 143(2): 621 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Gomez-Sanchez and E. P. Gomez-Sanchez Cardiac Steroidogenesis--New Sites of Synthesis, or Much Ado About Nothing? J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5118 - 5120. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Florian, A. Dorrance, R. C. Webb, and S. W. Watts Mineralocorticoids upregulate arterial contraction to epidermal growth factor Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R878 - R886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Dorrance, H. L. Osborn, R. Grekin, and R. C. Webb Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R944 - R950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Park and E. L. Schiffrin ETA Receptor Antagonist Prevents Blood Pressure Elevation and Vascular Remodeling in Aldosterone-Infused Rats Hypertension, June 1, 2001; 37(6): 1444 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rocha, C. T. Stier Jr., I. Kifor, M. R. Ochoa-Maya, H. G. Rennke, G. H. Williams, and G. K. Adler Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy Endocrinology, October 1, 2000; 141(10): 3871 - 3878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Takeda, T. Yoneda, M. Demura, I. Miyamori, and H. Mabuchi Cardiac Aldosterone Production in Genetically Hypertensive Rats Hypertension, October 1, 2000; 36(4): 495 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hatakeyama, S. Inaba, and I. Miyamori 11ß-Hydroxysteroid Dehydrogenase in Cultured Human Vascular Cells : Possible Role in the Development of Hypertension Hypertension, May 1, 1999; 33(5): 1179 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rocha, P. N. Chander, A. Zuckerman, and C. T. Stier Jr. Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats Hypertension, January 1, 1999; 33(1): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Takeda, S. Inaba, K. Furukawa, and I. Miyamori Renal 11ß-Hydroxysteroid Dehydrogenase in Genetically Salt-Sensitive Hypertensive Rats Hypertension, December 1, 1998; 32(6): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||